Efficacy of a Texting Program to Promote Cessation Among Pregnant Smokers: A Randomized Control Trial.

Published

Journal Article

INTRODUCTION: Smoking during pregnancy poses serious risks to baby and mother. Few disseminable programs exist to help pregnant women quit or reduce their smoking. We hypothesized that an SMS text-delivered scheduled gradual reduction (SGR) program plus support texts would outperform SMS support messages alone. METHODS: We recruited 314 pregnant women from 14 prenatal clinics. Half of the women received theory-based support messages throughout their pregnancy to promote cessation and prevent relapse. The other half received the support messages plus alert texts that gradually reduced their smoking more than 3-5 weeks. We conducted surveys at baseline, end of pregnancy, and 3 months postpartum. Our primary outcome was biochemically validated 7-day point prevalence abstinence at late pregnancy. Our secondary outcome was reduction in cigarettes per day. RESULTS: Adherence to the SGR was adequate with 70% responding to alert texts to smoke within 60 minutes. Women in both arms quit smoking at the same rate (9%-12%). Women also significantly reduced their smoking from baseline to the end of pregnancy from nine cigarettes to four; we found no arm differences in reduction. CONCLUSIONS: Support text messages alone produced significant quit rates above naturally occurring quitting. SGR did not add significantly to helping women quit or reduce. Sending support messages can reach many women and is low-cost. More obstetric providers might consider having patients who smoke sign up for free texting programs to help them quit. IMPLICATIONS: A disseminable texting program helped some pregnant women quit smoking.Clinical Trial Registration number: NCT01995097.

Full Text

Duke Authors

Cited Authors

  • Pollak, KI; Lyna, P; Gao, X; Noonan, D; Bejarano Hernandez, S; Subudhi, S; Swamy, GK; Fish, LJ

Published Date

  • June 12, 2020

Published In

Volume / Issue

  • 22 / 7

Start / End Page

  • 1187 - 1194

PubMed ID

  • 31647564

Pubmed Central ID

  • 31647564

Electronic International Standard Serial Number (EISSN)

  • 1469-994X

Digital Object Identifier (DOI)

  • 10.1093/ntr/ntz174

Language

  • eng

Conference Location

  • England